Comparison · NCT00312208-f73a5fb6
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Death From Any Cause (Overall Survival)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Death From Any Cause (Overall Survival). Trial comparisons, record NCT00312208-f73a5fb6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00312208-f73a5fb6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.113 | 0.099 | 0.13 | wilson | |
| Risk in group 2 | 0.122 | 0.108 | 0.139 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0091 | -0.0312 | 0.013 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.926 | 0.768 | 1.12 | log | |
| Odds ratio, group 1 over group 2 | 0.916 | 0.741 | 1.13 | log | |
| Number needed to treat, for one fewer participant with the outcome on Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) than on Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 110 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles. | 187 | 1,649 | OG000 |
| Group 2 | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel. | 202 | 1,649 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Death From Any Cause (Overall Survival)
- Description
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
- Time frame
- Median follow-up of 65 months
- Population
The analysis was performed on the Intent-to-Treat (ITT) population. Although the original Outcome Measure was intended to be presented as median survival time, median time-to-event was not reached in any group; therefore, number of participants who died was presented.
Source ClinicalTrials.gov
Trial
- Title
- Docetaxel in Breast Cancer
- NCT number
- NCT00312208
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- docetaxel, doxorubicin, cyclophosphamide, Docetaxel,doxorubicin, cyclophosphamide
- Lead sponsor
- Sanofi
- Results first posted
- 2010-02-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00312208?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00312208-f73a5fb6